EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells

An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskele...

Full description

Saved in:
Bibliographic Details
Published in:Mol Oncol
Main Authors: Chiu, Huan-Chih, Chang, Teng-Yuan, Huang, Chin-Ting, Chao, Yu-Sheng, Hsu, John T.-A.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2012
Subjects:
Papers
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528336/
https://ncbi.nlm.nih.gov/pubmed/22366308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.02.001
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items